Denali Therapeutics Inc. Common Stock (DNLI) Financials
Key financial figures for Denali Therapeutics Inc. Common Stock (Q3 2026).
AVLAYAH net product revenue reached $17.8 million in its second full commercial quarter, and Q4 2026 net product revenue is guided to $30.0 million to $32.0 million. Net product revenue of AVLAYAH (tividenofusp alfa-eknm) was $17.8 million for the quarter ended September 30, 2026, with no revenue in the year-ago quarter. Product revenue was $3.6 million in the second quarter (calculated as nine-month product revenue of $21.4 million less the third quarter). Net income was $70.1 million ($0.37 diluted per share), versus a net loss of $126.9 million ($0.74 per share) a year earlier. The quarter included a one-time $194.0 million net gain on the sale of a Priority Review Voucher; loss from operations was $126.8 million versus $137.4 million. On the outlook: Fourth-quarter 2026 AVLAYAH net product revenue is expected to be $30.0 million to $32.0 million. Figures are for Q3 2026, as Denali Therapeutics reported them.
- Revenue
- $18M
- Net Income
- $70M
- EPS
- $0.37
- Total Assets
- $1.3B
- Operating Cash Flow
- -$117M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $18M | $70M | $0.37 | -712.97% | -$118M |
| Q2 FY2026 | $4M | -$128M | -$0.68 | -3622.11% | -$98M |
| Q1 FY2026 | $0 | -$128M | -$0.69 | -$134M | |
| Q4 FY2025 | $0 | -$129M | -$0.73 | -$100M | |
| Q3 FY2025 | $0 | -$127M | -$0.74 |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $0 | -$513M | -$2.97 | -$422M | |
| FY2024 | $0 | -$423M | -$2.57 | -$364M | |
| FY2023 | $331M | -$145M | -$1.06 | -59.51% | -$371M |
Frequently asked questions
What was Denali Therapeutics's revenue last quarter?
Denali Therapeutics reported revenue of $17.8 million for Q3 FY2026.
Is Denali Therapeutics profitable?
Yes. Denali Therapeutics reported net income of $70.1 million for Q3 FY2026, a net margin of 394.45% on revenue.
How has Denali Therapeutics's margin trended?
Operating margin was -712.97% in Q3 FY2026. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Denali Therapeutics generate?
Denali Therapeutics generated free cash flow of -$118.5 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Denali Therapeutics Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.